急性冠脉综合征的诊断与治疗:一篇综述
该综述指出,ACS包括STEMI、NSTEMI和不稳定型心绞痛,全球每年超过700万人诊断为ACS。约79%男性和74%女性以静息胸部不适为首发症状,但约40%男性和48%女性表现为非特异性症状(如呼吸困难)。疑似ACS患者应在就诊10分钟内完成心电图;STEMI约占30%,NSTE-ACS约占70%。STEMI患者120分钟内直接PCI可使死亡率从9%降至7%;若无法在120分钟内PCI,可使用阿替普酶、瑞替普酶或替奈普酶溶栓(<75岁全剂量,≥75岁半剂量),随后转运目标为24小时内PCI。高危NSTE-ACS患者24–48小时内侵入性血管造影和血运重建可使死亡率从6.5%降至4.9%。
要点
- 疑似ACS患者应在就诊10分钟内完成心电图检查,以区分STEMI与非ST段抬高型ACS(NSTE-ACS)。
- STEMI约占ACS的30%,由冠状动脉完全闭塞引起;120分钟内直接PCI可使死亡率从9%降至7%。
- 若无法在120分钟内行PCI,<75岁且无禁忌者应给予全剂量阿替普酶、瑞替普酶或替奈普酶溶栓,≥75岁者给半剂量,随后转运目标为24小时内PCI。
- 高危NSTE-ACS且无禁忌者,24–48小时内行侵入性冠状动脉造影及经皮或外科血运重建,可使死亡率从6.5%降至4.9%。
- 高敏肌钙蛋白是评估NSTEMI的首选检测;NSTE-ACS约占ACS的70%,心电图可表现为ST段压低(约31%)、T波倒置(约12%)、两者兼有(16%)或均无(约41%)。
适用人群与场景
- 疑似急性冠脉综合征(ACS)的急诊就诊患者,包括STEMI、NSTEMI和不稳定型心绞痛。
- 全球每年估计超过700万人诊断为ACS,其中美国每年超过100万患者住院。
诊断标准与关键阈值
- 疑似ACS患者应立即行心电图检查(就诊10分钟内),以区分STEMI与非ST段抬高型ACS(NSTE-ACS)。
- STEMI:心电图提示ST段抬高,由冠状动脉完全闭塞引起,约占ACS的30%。
- NSTE-ACS:无显著ST段抬高,由动脉部分或间歇性闭塞引起,约占ACS的70%;心电图表现包括ST段压低(约31%)、T波倒置(约12%)、ST段压低合并T波倒置(16%)或两者均无(约41%)。
- 高敏肌钙蛋白是评估NSTEMI的首选检测。
处置流程与药物剂量
- 疑似ACS:立即行心电图检查(就诊10分钟内)。
- 心电图提示STEMI:若能在120分钟内完成直接PCI,应行快速再灌注治疗,可使死亡率从9%降至7%。
- 若无法在120分钟内行PCI:对<75岁且无禁忌者,给予全剂量阿替普酶、瑞替普酶或替奈普酶溶栓(若考虑费用问题可用全剂量链激酶);对≥75岁者给予半剂量;溶栓后转运至可行PCI的机构,目标为24小时内完成PCI。
- 高危NSTE-ACS且无禁忌者:24–48小时内行侵入性冠状动脉造影,并行经皮或外科血运重建,可使死亡率从6.5%降至4.9%。
红旗征与不能漏的情况
- 静息胸部不适是ACS最常见的就诊症状,约见于79%男性和74%女性。
- 约40%男性和48%女性表现为非特异性症状,如呼吸困难(单独出现或更常与胸痛并存),需警惕漏诊。
研究设计与关键结果
- 该综述汇总了ACS诊断与治疗的关键证据:全球每年超过700万人诊断为ACS;STEMI约占30%,NSTE-ACS约占70%。
- STEMI患者120分钟内直接PCI使死亡率从9%降至7%;若无法及时PCI,溶栓后转运目标为24小时内PCI。
- 高危NSTE-ACS患者24–48小时内侵入性评估和血运重建使死亡率从6.5%降至4.9%。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似ACS患者,确保就诊10分钟内完成心电图,以快速识别STEMI并启动再灌注流程。
- STEMI患者应优先在120分钟内行直接PCI;若无法实现,应按年龄和禁忌证选择全剂量或半剂量溶栓药物,并尽快转运至PCI中心(目标24小时内PCI)。
- 对高危NSTE-ACS且无禁忌者,应在24–48小时内安排侵入性冠状动脉造影和血运重建。
- 对表现为呼吸困难等非特异性症状的患者(尤其女性),应警惕ACS可能,避免漏诊。
指南或共识出处
- JAMA综述:急性冠脉综合征的诊断与治疗(Diagnosis and Treatment of Acute Coronary Syndromes: A Review)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Acute coronary syndromes (ACS) are characterized by a sudden reduction in blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina. Each year, an estimated more than 7 million people in the world are diagnosed with ACS, including more than 1 million patients hospitalized in the US.
OBSERVATIONS: Chest discomfort at rest is the most common presenting symptom of ACS and affects approximately 79% of men and 74% of women presenting with ACS, although approximately 40% of men and 48% of women present with nonspecific symptoms, such as dyspnea, either in isolation or, more commonly, in combination with chest pain. For patients presenting with possible ACS, electrocardiography should be performed immediately (within 10 minutes of presentation) and can distinguish between STEMI and non-ST-segment elevation ACS (NSTE-ACS). STEMI is caused by complete coronary artery occlusion and accounts for approximately 30% of ACS. ACS without significant ST-segment elevation on electrocardiography, termed NSTE-ACS, account for approximately 70% of ACS, are caused by partial or intermittent occlusion of the artery and are associated with ST-segment depressions (approximately 31%), T-wave inversions (approximately 12%), ST-segment depressions combined with T-wave inversions (16%), or neither (approximately 41%). When electrocardiography suggests STEMI, rapid reperfusion with primary percutaneous coronary intervention (PCI) within 120 minutes reduces mortality from 9% to 7%. If PCI within 120 minutes is not possible, fibrinolytic therapy with alteplase, reteplase, or tenecteplase at full dose should be administered for patients younger than 75 years without contraindications and at half dose for patients 75 years or older (or streptokinase at full dose if cost is a consideration), followed by transfer to a facility with the goal of PCI within the next 24 hours. High-sensitivity troponin measurements are the preferred test to evaluate for NSTEMI. In high-risk patients with NSTE-ACS and no contraindications, prompt invasive coronary angiography and percutaneous or surgical revascularization within 24 to 48 hours are associated with a reduction in death from 6.5% to 4.9%.
CONCLUSIONS AND RELEVANCE: Each year, an estimated more than 7 million people are diagnosed with ACS worldwide. For patients with STEMI, coronary catheterization and PCI within 2 hours of presentation reduces mortality, with fibrinolytic therapy reserved for patients without access to immediate PCI. For high-risk patients with NSTE-ACS without contraindications, prompt invasive coronary angiography followed by percutaneous or surgical revascularization is associated with lower rates of death.
参考来源
- Bhatt DL, Lopes RD, Harrington RA, et al. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022. PMID: 35166796. doi:10.1001/jama.2022.0358
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。